RhASA - Dose Level 2 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 19 | Lysosomal storage disease | 1 |
19. Lysosomal storage disease
Clinical trials : 899 / Drugs : 684 - (DrugBank : 99) / Drug target genes : 51 - Drug target pathways : 182
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00418561 (ClinicalTrials.gov) | January 22, 2007 | 4/1/2007 | Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD) | A Single Center, Open-label, Non-randomized, Uncontrolled, Multiple-dose, Dose Escalation Study of the Safety, Pharmacokinetics and Efficacy of Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD) | Metachromatic Leukodystrophy (MLD) | Biological: rhASA - Dose Level 1;Biological: rhASA - Dose Level 2;Biological: rhASA - Dose Level 3 | Shire | NULL | Completed | 1 Year | 5 Years | All | 13 | Phase 1 | Denmark |